Mirum Pharmaceuticals is a biopharmaceutical company focused on the identification, acquisition, development and commercialization of therapies for rare and orphan diseases. Co.'s focus is the development and commercialization of LIVMARLI® (maralixibat) oral solution (Livmarli) and volixibat. Livmarli is an oral solution approved as a once daily medicine for cholestatic pruritus in patients with Alagille syndrome one year of age and older. Co.'s second product candidate, volixibat, an oral, minimally-absorbed agent designed to inhibit ileal bile acid transporter, for the treatment of adult patients with cholestatic liver diseases. We show 20 historical shares outstanding datapoints in our MIRM shares outstanding history coverage, used to compute MIRM market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MIRM market cap history over the course of time is important for investors
interested in comparing MIRM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MIRM versus a peer is one thing; comparing
MIRM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MIRM can fluctuate over the course of history.
With this page we aim to empower investors researching MIRM by allowing them to research the MIRM market cap history. |
Free MIRM Email Alerts:
Video: The Importance of Market Cap
